Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2018 /
CheckMate142: Checkpoint combination therapy in first-line colorectal cancer

19th - 23rd Oct 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.10.18
Views: 532

Dr Heinz-Josef J. Lenz - Keck School of Medicine of USC, Los Angeles, USA

Dr Lenz speaks with ecancer at ESMO 2018 in Munich about the CheckMate 142 trial of nivolumab with ipilimumab as first-line therapy in DNA mismatch repair deficient (dMMR) and microsatellite instability-high (MSI-high) metastatic colorectal cancer (mCRC).

He outlines previous research into differing doses of the combination, and reports the improved disease control rate, response rate and tolerability of this trials 6 week schedule.

The use of checkpoint combination therapy in early colon cancer as neo-adjuvant therapy is also discussed by Dr Myriam Chalabi.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation